Advanced Solutions
for Advanced Pathology
Annexin A1 (MRQ-3)
Mouse Monoclonal Antibody
Cat. No. Description
Volume
44200 Annexin A1 RTU M (MRQ-3)
7 ml Ready To Use
44427 Annexin A1 0,1 M (MRQ-3)
100 µl liquid Concentrated
44428 Annexin A1 1 M (MRQ-3)
1 ml liquid Concentrated
Product Specifications
Designation
IVD
Reactivity
Paraffin
Visualization
Cytoplasmic, Membranous
Control
Hairy Cell Leukemia
Stability
Up to 36 mo. at 2-8°C
Isotype
IgG
1
Manual Protocol*
• Pretreatment: Heat Induced Epitope
Retrieval (HIER)
• Primary Antibody Incubation Time:
10-30min @ 25-37°C
• 2-step polymer detection
*Please refer to product insert for complete protocol.
Product Description
Annexin A1 (ANXA1) is strongly expressed on the cell membrane and occasionally in the cytoplasm of tumor cells in 97% of hairy cell leukemia.
By contrast, any B-cell lymphomas other than hairy cell leukemia (HCL), including typical splenic marginal zone lymphoma, variant hairy cell
leukemia, and prolymphocytic leukemia, are ANXA1-negative. Anti-ANXA1 has been reported as 100% sensitive and specific for hairy cell
leukemia. Normal mature B-cells were ANXA1-negative. The expression of ANXA1 in myeloid cells and T-cell subset serves as positive control.
ANXA1 is a molecule specific to HCL that can be used to differentiate this disease from other B-cell lymphomas. However, anti-ANXA1 is not a
suitable marker for monitoring minimal residual disease of HCL in bone marrow. A more suitable approach for assessment for residual disease
after therapy includes immunostaining using antibodies against CD20, T-bet, TRAcP, CD11c and DBA.44 in combination with anti-ANXA1.
B-cell Lymphomas
Annexin
A1
CD79a BCL6
CD10
CD23 Cyclin D1 CD5
MUM1 TRAcP CD11c
Follicular
-
+
+
+
-
-
-
-
-
CLL/SLL
-
+
-
-
+
-
+
+
-
-/+
Mantle Cell
-
+
-
-
-
+
+
-/+
-
-
Marginal Zone
-
+
-
-
-
-
-
+
+/-
+
Lymphoplasmacytic
-
+
-
-
-
-
-
+
-
-
Diffuse Large Cell
-
+
+
-/+
-
-
-/+
+
-
Burkitt
-
+
+
+
-
-
-
-
-
Hairy Cell Leukemia
+
+
-
-
-
+(weak)/-
-
+
+
Reference
1. Falini B, Tiacci E, et al. Lancet. 2004 Jun 5; 363(9424):1869-70. Erratum in:Lancet. 2004 Jun 26; 363(9427):2194.
2. Wang KL, Wu TT, et al. Clin Cancer Res. 2006 Aug 1; 12(15):4598-604.
3. Xia SH, Hu LP, et al. Oncogene. 2002 Sep 26; 21(43):6641-8.
4. Dreier R, Schmid KW, Gerke V, Riehemann K. Histochem Cell Biol. 1998 Aug; 110(2):137-48.
27
